Aualysis of Adverse Reactions During the Use of Rituximab for Lymphoma
OBJECTIVE To summarize the adverse reactions during the use of rituximab injection in the treat-ment of lymphoma and guide clinical medication.METHODS A retrospective analysis was conducted on 109 pa-tients with B-cell lymphoma admitted to our hospital from May 2019 to December 2023,and the incidence of adverse reactions in this group of patients was statistically analyzed.RESULTS(1)Among the 109 cases,diffuse large B-cell lymphoma patients were the most common,accounting for 64.22％;(2)From the treatment plan of rituximab in-jection,22 cases were treated with rituximab alone,accounting for 20.18％,and 87 cases were treated with combina-tion therapy,accounting for 79.82％.The R-CHOP regimen(mainly Doxorubicin or Doxorubicin)in the combination therapy regimen accounts for 64.22％;(3)From the perspective of adverse reactions involving the system or organs caused by rituximab injection,the hematological system had the most adverse reactions,with a total of 60 cases,ac-counting for 55.04％,followed by the digestive system with 44 cases,accounting for 40.37％.(4)Rituximab injec-tion had the highest grade Ⅱ adverse reactions in the blood system,with a total of 30 cases,accounting for 50.00％;The degree of adverse reactions in the digestive system is the highest,accounting for 63.63％.CONCLUSION When using rituximab injection to treat lymphoma,patients may experience various adverse reactions.Therefore,med-ication management should be standardized to prevent and reduce adverse reactions as much as possible.
万方数据
维普
